2023
Biomarker analysis to predict response in patients with metastatic mismatch repair proficient colorectal cancer treated with regorafenib and nivolumab.
Miao R, Kim D, Yu J, Kovari B, Mehta R, Strosberg J, Imanirad I, Iyer S, Uhlik M, Benjamin L, Kim R. Biomarker analysis to predict response in patients with metastatic mismatch repair proficient colorectal cancer treated with regorafenib and nivolumab. Journal Of Clinical Oncology 2023, 41: 228-228. DOI: 10.1200/jco.2023.41.4_suppl.228.Peer-Reviewed Original ResearchProgression free survivalMedian progression free survivalTreated with regorafenibOverall survivalPD-L1Tumor microenvironmentColorectal cancerMedian OSCD8 expressionPartial responseTreg cellsImmune desertPredictive biomarkersAssociated with prolonged progression free survivalMismatch repair-proficient colorectal cancersProlonged progression free survivalDisease control ratePhase I/Ib studyPredicting clinical benefitPD-L1 expressionPretreatment tumor samplesPotential predictive biomarkersPMMR colorectal cancerBiomarker-positiveBiomarker-negative patients
2020
RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.
Posadas E, Gay H, Pugh S, Morgan T, Yu J, Lechpammer S, Feng F. RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery. Journal Of Clinical Oncology 2020, 38: tps5601-tps5601. DOI: 10.1200/jco.2020.38.15_suppl.tps5601.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression-free survivalHigh-risk featuresSalvage radiotherapyBiochemical recurrenceRadical prostatectomyProstate cancerSystemic therapyAndrogen receptorYears of androgen deprivation therapyOccurrence of biochemical failureStandard androgen deprivation therapyRandomized phase II studyIndividualization of radiotherapyNon-steroidal anti-androgenPersistently elevated PSADisease control rateRecurrent prostate cancerSeminal vesicle invasionPara-aortic nodesSuspicious lymph nodesPatient-reported toxicityRisk of progressionOne-sided alphaElevated PSA